GLP-1(7-37) acetate|cas:1450806-98-0|西域试剂

GLP-1(7-37) acetate,99.33%

产品编号：Bellancom-P0055A| CAS NO：1450806-98-0| 分子式：C₁₅₃H₂₃₂N₄₀O₄₉| 分子量：3415.72

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P0055A	￥1400.00	杭州北京（现货）
Bellancom-P0055A	￥2800.00	杭州北京（现货）
Bellancom-P0055A	￥4200.00	杭州北京（现货）
Bellancom-P0055A	￥8200.00	杭州北京（现货）
Bellancom-P0055A	￥12500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

GLP-1(7-37) acetate

产品介绍

GLP-1(7-37) acetate 是一种肠道胰岛素激素，可以增强葡萄糖诱导的胰岛素分泌。

生物活性

GLP-1(7-37) acetate is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.

体外研究

体内研究

GLP-1(7-37) (0.5, 5 or 50 pmol/min/kg) infused during the second hour of a 2-hour 11-mM hyperglycemic clamp produces a dose-related enhancement of the glucose-stimulated increase in plasma insulin concentration and an increased rate of glucose infusion in rats.
Infusion of GLP-1(7-37) (5 pmol/min/kg) from 1 hour through 7 hours produces a sustained increase in plasma insulin concentration relative to levels in rats infused with vehicle in rats with maintained glucose concentration at 11 mM.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats weighing 300 to 350 g with glucose IV at a variable rate for 7 hours to maintain plasma glucose concentration at 11 mM.
Dosage:	5 pmol/min/kg.
Administration:	IV from 1 hour through 7 hours.
Result:	Produced a sustained increase in plasma insulin concentration relative to levels in rats infused with vehicle.

Animal Model:	Male Sprague-Dawley rats weighing 300 to 350 g with maintained plasma glucose concentration at 11 mM.
Dosage:	0.5, 5 or 50 pmol/min/kg.
Administration:	IV during the second hour of a 2-hour 11-mmol/L hyperglycemic clamp.
Result:	Produced a dose-related enhancement of the glucose-stimulated increase in plasma insulin concentration and an increased rate of glucose infusion.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats weighing 300 to 350 g with glucose IV at a variable rate for 7 hours to maintain plasma glucose concentration at 11 mM.
Dosage:	5 pmol/min/kg.
Administration:	IV from 1 hour through 7 hours.
Result:	Produced a sustained increase in plasma insulin concentration relative to levels in rats infused with vehicle.

Animal Model:	Male Sprague-Dawley rats weighing 300 to 350 g with maintained plasma glucose concentration at 11 mM.
Dosage:	0.5, 5 or 50 pmol/min/kg.
Administration:	IV during the second hour of a 2-hour 11-mmol/L hyperglycemic clamp.
Result:	Produced a dose-related enhancement of the glucose-stimulated increase in plasma insulin concentration and an increased rate of glucose infusion.

性状

Solid

溶解性数据

In Vitro:

H₂O : 50 mg/mL (14.64 mM; ultrasonic and adjust pH to 1 with HCl)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.2928 mL	1.4638 mL	2.9276 mL
5 mM	0.0586 mL	0.2928 mL	0.5855 mL
10 mM	0.0293 mL	0.1464 mL	0.2928 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶